Taysha Gene Therapies Files 8-K on Shareholder Vote Matters
Ticker: TSHA · Form: 8-K · Filed: May 30, 2024 · CIK: 1806310
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, disclosure
TL;DR
Taysha Gene Therapies filed an 8-K regarding shareholder vote matters from May 29th.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on May 30, 2024, reporting on a submission of matters to a vote of security holders that occurred on May 29, 2024. The company, incorporated in Delaware, is involved in biological products and is headquartered in Dallas, Texas.
Why It Matters
This filing indicates a formal process where Taysha Gene Therapies is seeking or reporting on decisions made by its shareholders, which could impact corporate governance and future strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
- May 30, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing does not specify the exact matters submitted to a vote, only that such a submission occurred on May 29, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 29, 2024.
What is Taysha Gene Therapies, Inc.'s principal executive office address?
The principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for Taysha Gene Therapies, Inc. is 84-3199512.
What is the Standard Industrial Classification code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-30 16:02:02
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d805768d8k.htm (8-K) — 28KB
- 0001193125-24-150323.txt ( ) — 151KB
- tsha-20240529.xsd (EX-101.SCH) — 3KB
- tsha-20240529_lab.xml (EX-101.LAB) — 18KB
- tsha-20240529_pre.xml (EX-101.PRE) — 11KB
- d805768d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: May 30, 2024 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer